Information Provided By:
Fly News Breaks for June 13, 2017
Jun 13, 2017 | 14:15 EDT
Ladenburg analyst Matthew Kaplan was "impressed" with the results from pSivida's second Phase 3 trial of Durasert, which he said strongly confirm the efficacy and safety seen in the earlier study and can serve as the basis for a U.S. NDA filing. The company currently plans an NDA filing by Q4 and plans to commercialize Durasert via a contract sales organization, noted Kaplan, who reiterates a Buy rating and $12.50 price target on the stock, which is down 32c, or 15%, to $1.76 in afternoon trading.
News For PSDV From the Last 2 Days
There are no results for your query PSDV
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.